anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study aimed to translate and culturally adapt the standardized outcomes in nephrology-hemodialysis fatigue (SONG-HD fatigue) scale and to assess the psychometric properties of the Chinese version of the SONG-HD fatigue (C-SONG-HD fatigue) scale.
METHODS: Forward and back translations were used to translate the SONG-HD fatigue scale into Chinese. We used the C-SONG-HD fatigue scale to survey Chinese patients undergoing hemodialysis (HD) in China. We examined the distribution of responses and floor and ceiling effects. Cronbach's alpha and McDonald's omega coefficient, intraclass coefficients, and Spearman correlations were used to assess internal consistency reliability, test-retest reliability, and convergent validity, respectively. Responsiveness was also evaluated.
RESULTS: In total, 489 participants across southeast China, northwest China, and central China completed the study. The C-SONG-HD fatigue scale had good internal consistency (Cronbach's alpha coefficient 0.861, omega coefficient 0.916), test-retest reliability (intraclass correlation coefficient 0.695), and convergent validity (Spearman correlation 0.691). The analysis of all first-time HD patients did not show notable responsiveness, and only patients with temporary vascular access had good responsiveness with an effect size (ES) of 0.54, a standardized response mean (SRM) of 0.85, and a standard error of measurement (SEM) of 0.77.
CONCLUSION: The Chinese version of the SONG-HD fatigue scale showed satisfactory reliability and validity in patients undergoing hemodialysis (HD) in China. It could be used as a tool to measure the fatigue of Chinese HD patients.
Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
The extensive exploration of the correlation between electroencephalogram (EEG) and heart rate variability (HRV) has yielded inconsistent outcomes, largely attributable to variations in the tasks employed in the studies. The direct relationship between EEG and HRV is further complicated by alpha power, which is susceptible to influences such as mental fatigue and sleepiness. This research endeavors to examine the brain-heart interplay typically observed during periods of music listening and rest. In an effort to mitigate the indirect effects of mental states on alpha power, subjective fatigue and sleepiness were measured during rest, while emotional valence and arousal were evaluated during music listening. Partial correlation analyses unveiled positive associations between occipital alpha2 power (10-12 Hz) and nHF, an indicator of parasympathetic activity, under both music and rest conditions. These findings underscore brain-heart interactions that persist even after the effects of other variables have been accounted for.
Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter. Cohort E will seek to validate the immunohistochemical (IHC)-based biomarker strategy, by characterizing the activity of Amivantamab and Lazertinib combination in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC. In addition, Cohort E will seek to collect prospective data to confirm that prophylactic anticoagulation safely and effectively decreases the incidence of VTE events for patients treated with the combination of Amivantamab and Lazertinib, using Cohort F as reference.
Methods for prevention and treatment of asthma attacks involve the administration of one or more TRPV1 antagonists, one or more LPAr antagonists or preferably a combination of one or more TRPV1 antagonists and one or more LPAr antagonists. TRPV1 antagonists and/or LPAr antagonists or a combination of both inhibit or prevent carotid body activation during an acute asthma attack. TRPV1 antagonists, LPAr antagonists or a combination thereof are useful for preventing or ameliorating the symptoms of asthma attacks. Pharmaceutical compositions for use in treating asthma and more specifically for preventing or treating asthma attacks comprise a combination of a TRPV1 antagonist and an LPAr antagonist. Methods for making medicaments for such treatment are provided. Also provided are kits for treating asthma and for preventing or treating asthma attacks in which a TRPV1 antagonist and an LPAr antagonist are separately formulated for administration at the same time.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anaesthesiology and resuscitation, and can be used as an anaesthesia care in required surgeries of pelvic fractures and damages of inferior limbs. That is ensured by puncture of the epidural cavity. 0.75% Naropin is preheated to temperature 40-42C and thereafter introduced in amount 13-20 ml into an epidural catheter with an assisting temperature sensor. The solution is injected into the epidural catheter as soon as its temperature is decreased to 36C and lower, until the temperature is decreased to 30C and lower. ^ EFFECT: method provides reduced time for a complete block in epidural anaesthesia combined with decreasing a dose of Naropin due to decreasing the dissociation constant and increasing a non-ionised drug fraction ensured by certain temperature of anaesthetic introduction. ^ 1 dwg, 2 ex
ColonAiQ polygene methylation test was performed on peripheral blood plasma samples from the enrolled patients 4 weeks after surgery. If gene methylation levels in the samples exceeded the threshold, the patients were enrolled in the MRD positive group. The 2-year total tumor recurrence rate of patients in the MRD positive group was calculated, and the positive prediction rate of postoperative plasma ctDNA methylation-MRD detection results for 2-year tumor recurrence rate after colorectal cancer radical resection was calculated.
The invention discloses an armeniaca sibirica oil skin-moisturizing lotion and a preparation method thereof. The lotion comprises the components of, by mass, 10-20% of detoxified armeniaca sibirica oil, 0.15-0.5% of hyaluronic acid, 2-5% of lubrajel, 2-4% of cetanol, 0.5-1.5% of an emulsifying agent, 1-2% of stearic acid, 0.1-0.5% of a fragrance, 0.2-0.5% of an antibacterial agent, and balance of deionized water. Armeniaca sibirica oil has high unsaturated fatty acid content and good permeation on skins. The effective components in the product can be rapidly absorbed by skin. Therefore, when the armeniaca sibirica oil skin-moisturizing lotion is applied on face, no greasy sensation is caused. With the lotion, a moisturizing and nourishing effect is substantial. The lotion is especially suitable for northern arid and semi-arid regions.
BACKGROUND: Hypoxic-ischemic encephalopathy (HIE) is a severe neonatal complication that can result in 40-60 % of long-term morbidity. Magnetic Resonance Imaging (MRI) is a noninvasive method which is usually performed before discharge to visually assess acquired cerebral lesions associated with HIE and severity of lesions possibly providing a guide for detecting adverse outcomes. This study aims to evaluate the impact of HIE on brain volume changes observed in MRI scans performed at a mean 10 days of life, which can serve as a prognostic indicator for abnormal neurodevelopmental (ND) outcomes at 18-24 months among HIE infants.
METHODS: We retrospectively identified a cohort of HIE patients between June 2013 and March 2017. The inclusion criteria for therapeutic hypothermia (TH) were a gestational age ≥35 weeks, a birth weight ≥1800 g, and the presence of ≥ moderate HIE. Brain MRI was performed at a mean 10 days of life and brain volumes (total brain volume, cerebral volume, cerebellar volume, brain stem volume, and ventricle volume) were measured for quantitative assessment. At 18-24 months, the infants returned for follow-up evaluations, during which their cognitive, language, and motor skills were assessed using the Bayley Scales of Infant and Toddler Development III.
RESULTS: The study recruited a total of 240 infants between 2013 and 2017 for volumetric brain MRI evaluation. Among these, 83 were normal control infants, 107 were TH-treated HIE infants and 37 were HIE infants who did not receive TH due to contraindications. Clinical evaluation was further proceeded. We compared the brain volumes between the normal control infants (n = 83) with normal ND but TH-treated HIE infants (n = 76), abnormal ND TH-treated HIE infants (n = 31), and the severe HIE MRI group with no TH (n = 37). The abnormal ND TH-treated HIE infants demonstrated a significant decrease in brainstem volume and an increase in ventricle size (p < 0.001) (Table 4). Lastly, the severe brain MRI group who did not receive TH showed significantly smaller brain stem (p = 0.006), cerebellar (p = 0.006) and cerebrum volumes (p = 0.027), accompanied by larger ventricular size (p = 0.013) compared to the normal control group (Table 5).
CONCLUSION: In addition to assessing the location of brain injuries in MRI scans, the reduction in brain stem volume coupled with an increase in ventricular volume in HIE infants may serve as a biomarker indicating severe HIE and adverse long-term ND outcomes among HIE infants who either received therapeutic hypothermia (TH) treatment or not.
OBJECTIVE: The aims of this study were to 1) define the incidence of transforaminal lumbar interbody fusion (TLIF) interbody subsidence; 2) determine the relative importance of preoperative and intraoperative patient- and instrumentation-specific risk factors predictive of postoperative subsidence using CT-based assessment; and 3) determine the impact of TLIF subsidence on postoperative complications and fusion rates.
METHODS: All adult patients who underwent one- or two-level TLIF for lumbar degenerative conditions at a multi-institutional academic center between 2017 and 2019 were retrospectively identified. Patients with traumatic injury, infection, malignancy, previous fusion at the index level, combined anterior-posterior procedures, surgery with greater than two TLIF levels, or incomplete follow-up were excluded. Interbody subsidence at the superior and inferior endplates of each TLIF level was directly measured on the endplate-facing surface of both coronal and sagittal CT scans obtained greater than 6 months postoperatively. Patients were grouped based on the maximum subsidence at each operative level classified as mild, moderate, or severe based on previously documented < 2-mm, 2- to 4-mm, and ≥ 4-mm thresholds, respectively. Univariate and regression analyses compared patient demographics, medical comorbidities, preoperative bone quality, surgical factors including interbody cage parameters, and fusion and complication rates across subsidence groups.
RESULTS: A total of 67 patients with 85 unique fusion levels met the inclusion and exclusion criteria. Overall, 28% of levels exhibited moderate subsidence and 35% showed severe subsidence after TLIF with no significant difference in the superior and inferior endplate subsidence. Moderate (≥ 2-mm) and severe (≥ 4-mm) subsidence were significantly associated with decreases in cage surface area and Taillard index as well as interbody cages with polyetheretherketone (PEEK) material and sawtooth surface geometry. Severe subsidence was also significantly associated with taller preoperative disc spaces, decreased vertebral Hounsfield units (HU), the absence of bone morphogenetic protein (BMP) use, and smooth cage surfaces. Regression analysis revealed decreases in Taillard index, cage surface area, and HU, and the absence of BMP use predicted subsidence. Severe subsidence was found to be a predictor of pseudarthrosis but was not significantly associated with revision surgery.
CONCLUSIONS: Patient-level risk factors for TLIF subsidence included decreased HU and increased preoperative disc height. Intraoperative risk factors for TLIF subsidence were decreased cage surface area, PEEK cage material, bullet cages, posterior cage positioning, smooth cage surfaces, and sawtooth surface designs. Severe subsidence predicted TLIF pseudarthrosis; however, the causality of this relationship remains unclear.
The present invention provides the method to prevent or slow down the progression of degenerative diseases caused by membrane channel-forming peptides. For many of these diseases, there is no known treatment based on the etiology and pathogenesis of the corresponding disease. Until recently, there was no integrative theory explaining multiple symptoms and observations associated with such diseases. In response to this challenge, we developed the amyloid degradation toxicity theory of Alzheimer's disease (AD). Within this concept, the etiology of the disease is the formation of beta-amyloid fragments which form membrane channels. We claim that the stopping the production of toxic fragments by inhibiting biochemical pathways producing channel-forming fragments (for example, by protease inhibitors) will prevent or slow down the progression AD. Also, we claim that the same molecular mechanism is involved in multiple neurodegenerative diseases and diabetes type II, so the invented method can be used to treat them.
Composition containing a continuous liquid fatty phase gelled or thickened with at least one fatty acid ester of dextrin with a degree of substitution of less than 2 on the basis of one repeating unit, for example one glucose unit.  Composition containing a continuous liquid fatty phase gelled or thickened with at least one fatty acid ester of dextrin with a degree of substitution of less than 2 on the basis of one repeating unit, for example one glucose unit. The fatty phase contains an oil or a mixture of oils that has solubility parameters deltad, deltap and deltah satisfying equation (1). (4(deltad-deltade)2 + (deltap-deltape)2 + (deltah-deltahe)2 )1/2 at most 10 (1) deltade, deltape and deltahe are the solubility parameters of the dextrin ester, the liquid fatty phase and the dextrin ester forming a physiologically acceptable medium. An Independent claim is also included for a composition containing a mixture of fatty acid esters of dextrins. One has a degree of substitution less than 2, and one with a degree of substitution greater than 2.
The invention relates to a camellia chrysantha activity of assisting hypoglycemic effect, and a camellia chrysantha capsule assisting hypoglycemic effect and a preparation method thereof. A prescription of the camellia chrysantha capsule assisting hypoglycemic effect is as below: 33-66% of camellia chrysantha extractive and 67-34% of pharmaceutic adjuvant. The preparation method comprises steps of: weighing the camellia chrysantha extractive and the pharmaceutic adjuvant according to the prescription, and preparing into hard capsules. The camellia chrysantha extractive is obtained by immersing, extracting and concentrating the camellia chrysantha with a proper solvent; the pharmaceutic adjuvant is medicinal starch or dextrin, or a mixture of the two; and the solvent is water or ethanol, or a mixture of the two. The camellia chrysantha capsule has substantial hypoglycemic effect on high blood sugar mice caused by alloxan. The camellia chrysantha capsule of the invention and the assistant hypoglycemic effect thereof have not been reported and are discovered by the inventor through experiments; therefore, the invention is applied to be protected by patent right.
NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
Anxiety disorders are among the most common mental disorders in children and adolescents, and they are associated with short- and long-term impairment in social, academic, familial, and psychological functioning. The children of parents with anxiety disorders are more likely to develop anxiety disorders themselves, because of genetic factors and the atmosphere in which they are raised. Previous research indicates that the risk of anxiety disorders among children can be reduced through preventive therapeutic interventions. In children with anxiety disorders whose parents also have anxiety disorders, therapy that includes their family is more successful than therapy focused only on the child. This study will test the effectiveness of a preventive, family-based therapy for children whose parents have anxiety disorders.

Participation in this study will last 1 year. First, interested participants will be asked to perform a screening assessment. This will include providing information about the symptoms, behaviors, and functioning of parent and child participants; filling out questionnaires; and videotaping the child and parent participants interacting. If, after the screening, participants are selected to continue with the study, they will be randomly assigned to receive either information monitoring or family-based cognitive behavioral therapy. Child and parent participants assigned to information monitoring will receive a booklet with information on coping with anxiety. Child and parent participants assigned to family-based cognitive behavioral therapy will meet with a study clinician for eight, weekly, 1-hour intervention visits, during which participants will learn skills to reduce anxiety. After completing the weekly visits, participants in this group will also receive three monthly booster sessions, in which coping skills will be reviewed. In addition to the screening visit, all participants will undergo identical assessments at three more time periods: 9 weeks, 6 months, and 12 months after entering the study. All participants will also receive monthly phone calls throughout the study to monitor the children's anxiety symptoms.
Proquin XR was evaluated for the treatment of uncomplicated urinary tract infections (acute cystitis) in a randomized, double-blind, controlled trial conducted in the US. This study compared Proquin XR (500 mg once daily for 3 days) with ciprofloxacin immediate-release tablets (CIPRO® 250 mg twice daily for 3 days). Of the 1,037 patients enrolled, 524 were randomly assigned to the Proquin XR treatment group and 513 were randomly assigned to the control group. A total of 272 (52%) patients in the Proquin XR group and 251 (49%) in the CIPRO group were evaluable for efficacy and included in the Per-Protocol population. The primary efficacy variable was bacteriologic eradication of the baseline organism(s) with no new infection at the Test-of-Cure (TOC) visit (Day 4 to 11 post-therapy).

The bacteriological eradication and clinical success rates were similar for both treatment groups. The eradication and clinical success rates and their corresponding 95% confidence intervals for the differences between rates (Proquin XR minus control group) are given in the following table:

The bacteriological eradication rates for baseline organisms at the TOC visit were 93% (254/272) for Proquin XR and 90% (225/251) for CIPRO. Of the patients with their baseline organism eradicated, new infections were detected in 42/254 (16.5%) Proquin XR-treated patients and 32/225 (14.2%) CIPRO-treated patients at the TOC visit. Gram-negative rods were responsible for new infections in 10 Proquin XR-treated patients and 7 CIPRO-treated patients, and Enterococcus species were isolated in 24 Proquin XR-treated patients, and 20 CIPRO-treated patients.
After a baseline breast tumor core biopsy, eligible women with triple negative breast cancer (ER- alpha, PR and HER-2 receptor negative) will be treated with S-equol at a dose of 50 mg twice daily for a period of about 14 days (10-21 day range). After completion of treatment, a second breast tumor sample will be obtained to compare molecular changes between the two specimens. The second pathology specimen may be from the surgical resection of the breast tumor, or a repeat core needle biopsy, if no further surgery is planned. The primary endpoint will be the absolute change in the Ki67, which is a validated marker of tumor proliferation in breast cancer. Secondary endpoints will include assessment of total ER-beta and pY36 levels as measured by immunohistochemical staining and their correlation with S-equol effects. Further treatment after surgical resection or second core needle biopsy of the tumor will be guided by tumor size, nodal status and other standard parameters, and is at the discretion of the treating physician. The Investigator hypothesizes that S-equol will cause a measurable decrease in Ki-67 in estrogen receptor beta expressing triple negative breast cancers, indicating its potential efficacy in this tumor type.
The phase Ib segment will be carried out in a standard 3+3 design. In the phase II portion, 2 parallel cohorts will be enrolled (Cohort A: 1q21.3 amplified breast cancers, Cohort B: 1q21.3 amplified other solid tumors).
PURPOSE:To obtain the titled extraction fraction and extract useful as an antidiabetic agent free from side effects, in high purity, by extracting the corns of hop with a specific extractant, and evaporating the extraction solvent to dryness. CONSTITUTION:The corns of hop are extracted with an alcohol, the alcohol is distilled off, the residue is extracted with ether, the ether is distilled off, the residue is further extracred with alcohol, the alcohol is distilled off, and the residue is tracted with n-hexane. The treated residue is separated into n-hexane- souble fraction and the insoluble fraction. n-Hexane is distilled off from the n-hexane-soluble fraction to obtain the objective active component. Other active component of antidiabetic agent can also be obtained from the n-hexane-insoluble fraction. The ingredient components which do not participate in the antidiabetic action can be removed from hop by the above extraction treatment with the extraction solvent, and a fraction having strong durg action can be obtained. The component is an antidiabelic agent of a new type free from hypoglycemic phenomenon and the increase in the lactic acid level in blood.
Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
The present invention relates to stable personal care composition, including oral care compositions containing a peroxide source. The compositions are stabilized by eliminating or minimizing the presence in the composition of metals having radical forming potential with the peroxide. Preferably, the metals that are eliminated or reduced are cobalt, copper, palladium, nickel and iron. The compositions are further stabilized by the addition of agents having scavenging or quenching activity for free radicals. Reducing free radical activity in the product matrix prevents radical- mediated loss and degradation of peroxide and other ingredients, in particular organic compounds added as active or aesthetic agents, including flavors, perfumes, colorants and thickeners. Provided are peroxide containing oral care products with enhanced consumer appeal in terms of taste, mouthfeel and appearance, thereby encouraging compliance and regular use. Such attributes are important since use of these products may involve fairly long residence time in the mouth for efficacy.
Machine training and application of machine-trained classifier are used for image-based tumor phenotyping in a medical system. To create a training database with known phenotype information, synthetic medical images are created. A computational tumor model creates various examples of tumors in tissue. Using the computational tumor model allows one to create examples not available from actual patients, increasing the number and variance of examples used for machine-learning to predict tumor phenotype. A model of an imaging system generates synthetic images from the examples. The machine-trained classifier is applied to images from actual patients to predict tumor phenotype for that patient based on the knowledge learned from the synthetic images.